Live tape
Top 8, mentions 7d8,858GOOGL1,691 mentions▲ +0.04MRNA1,354 mentions▲ +0.09SNDK1,285 mentions▲ +0.11META1,126 mentions▲ +0.03NVDA1,045 mentions▲ +0.08SPCX899 mentions▲ +0.08NBIS744 mentions▲ +0.09MSFT714 mentions▲ +0.05

Equity · Healthcare

TGTX

TG Therapeutics, Inc. · NasdaqCM

$55 +0.16% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 38 sessions
$60 $30 22 May 17 Jul

The line runs $39 on 22 May through $55 on 17 July, on a scale from $30 to $60. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of TGTX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 38 sessions over that window: $39 on 22 May 2026 through $55 on 17 July 2026.

Market cap $8.4B
P/E (TTM) 19.9
52-week range $26.40 – $59
Avg volume 431.4K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026

TGTX insider trades

SEC Form 4

TGTX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 24 November 2025.

Date Insider Type Shares Value
24 Nov 2025 Echelard Yann Sell 5,000 $163K
11 Sep 2025 Lonial Sagar Sell 20,852 $672K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
05 Nov 2025 WEISS MICHAEL S CEO Gift 4,668,843

TGTX reported financials

SEC EDGAR XBRL

TGTX reported revenue of $616.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was $447.2M.

Figure Reported Period
Revenue $616.3M 31 Dec 2025 fiscal year
Net income $447.2M 31 Dec 2025 fiscal year
Diluted EPS $2.77 31 Dec 2025 fiscal year
Total assets $1.6B 30 Jun 2026 at period end
Total equity $604.1M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

TGTX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.05 —
31 Mar 2026 Q1 2026 $0.12 —
31 Dec 2025 FY 2025 $2.77 —
30 Sep 2025 Q3 2025 $2.43 —
30 Jun 2025 Q2 2025 $0.17 —
31 Mar 2025 Q1 2025 $0.03 —
31 Dec 2024 FY 2024 $0.15 —
30 Sep 2024 Q3 2024 $0.02 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

TGTX institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a TGTX position for the quarter ended 30 Jun 2026 — a combined $479.5M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
D. E. Shaw & Co. Added +476.4% shares 3,400,808 $186.8M
Two Sigma Investments Added +60.1% shares 2,468,971 $135.6M
Renaissance Technologies Added +99.3% shares 679,300 $37.3M
Citadel Advisors Trimmed −72.1% shares 537,170 $29.5M
AQR Capital Management Added +28.5% shares 442,287 $24.3M
Bridgewater Associates Added +38.0% shares 429,904 $23.6M
Millennium Management Added +122.3% shares 272,511 $15.0M
Point72 Asset Management New position 264,963 $14.6M
Man Group Trimmed −62.7% shares 132,376 $7.3M
Tudor Investment Corp New position 93,920 $5.2M

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

TGTX fails-to-deliver

SEC CNS data

On 29 Jul 2026, 997 shares of TGTX failed to deliver (about $55K).

Settlement date Shares failed Notional % of shares out
29 Jul 2026 997 $55K 0.001%
27 Jul 2026 80 $4K <0.001%
24 Jul 2026 1,764 $98K 0.001%
23 Jul 2026 88 $5K <0.001%
13 Jul 2026 2 $114 <0.001%
10 Jul 2026 9,353 $552K 0.006%
08 Jul 2026 6,818 $396K 0.004%
07 Jul 2026 85,182 $4.7M 0.056%
06 Jul 2026 42,373 $2.3M 0.028%

Source: SEC fails-to-deliver (CNS) data